Intravenous heterologous prime-boost vaccination activates innate and adaptive immunity to promote tumor regression
Cell Reports · 2023-06 · 42 (6) · 112599
DOI: 10.1016/j.celrep.2023.112599 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Reports, 2023-06. Verfasst von Ramiro A Ramirez-Valdez und 13 weiteren Autor:innen. Beteiligte Einrichtung: Vaccine Research Center, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD, USA; Ludwig Institute for…. Hauptthemen laut MEDLINE: Vaccination, CD8-Positive T-Lymphocytes. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Intramural NIH HHS.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Vaccine Research Center, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD, USA; Ludwig Institute for Cancer Research, Nuffield Department of Medicine, University of Oxfor…
- Vaccine Research Center, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD, USA.
- Singapore Immunology Network, A(∗)STAR, Singapore, Singapore; Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
- Vaccitech North America, Baltimore, MD, USA.
- Singapore Immunology Network, A(∗)STAR, Singapore, Singapore; Translational Immunology Institute, SingHealth Duke-NUS Academic Medical Centre, Singapore, Singapore.
- Singapore Immunology Network, A(∗)STAR, Singapore, Singapore; Translational Immunology Institute, SingHealth Duke-NUS Academic Medical Centre, Singapore, Singapore; Institut National de la Sante et de la Recherche Medic…
Förderung
- Intramural NIH HHS
Zitieren
APA
Ramirez-Valdez, R. A., Baharom, F., Khalilnezhad, A., Fussell, S. C., Hermans, D. J., Schrager, A. M., Tobin, K. K. S., Lynn, G. M., Khalilnezhad, S., Ginhoux, F., Van den Eynde, B. J., Leung, C. S. K., Ishizuka, A. S., & Seder, R. A. (2023). Intravenous heterologous prime-boost vaccination activates innate and adaptive immunity to promote tumor regression. Cell Reports, 42(6), 112599. https://doi.org/10.1016/j.celrep.2023.112599
Vancouver
Ramirez-Valdez RA, Baharom F, Khalilnezhad A, Fussell SC, Hermans DJ, Schrager AM, et al. Intravenous heterologous prime-boost vaccination activates innate and adaptive immunity to promote tumor regression. Cell Reports. 2023;42(6):112599. doi:10.1016/j.celrep.2023.112599
BibTeX
@article{RamirezValdez2023,
author = {Ramirez-Valdez, Ramiro A and Baharom, Faezzah and Khalilnezhad, Ahad and Fussell, Sloane C and Hermans, Dalton J and Schrager, Alexander M and Tobin, Kennedy K S and Lynn, Geoffrey M and Khalilnezhad, Shabnam and Ginhoux, Florent and Van den Eynde, Benoit J and Leung, Carol Sze Ki and Ishizuka, Andrew S and Seder, Robert A},
title = {Intravenous heterologous prime-boost vaccination activates innate and adaptive immunity to promote tumor regression},
journal = {Cell Reports},
year = {2023},
volume = {42},
number = {6},
pages = {112599},
doi = {10.1016/j.celrep.2023.112599}
}
EUVIMED